Cardiovascular disease
Conditions
Interventions
Control group:Take a placebo daily (2 tablets per dose, twice daily)
Vitamin group:Take vitamins (folic acid, vitamin B6 and B12) daily and a placebo (1 tablet of vitamins and 1 tablet of placebo each time, twice a day)
Metformin group:Take metformin and a placebo daily (1 tablet of metformin and 1 tablet of placebo per dose, twice daily)
Metformin combined with vitamins group:Take metformin plus vitamins (folic acid, vitamin B6, and B12) daily (1 tablet of metformin and 1 tablet of vitamins per dose, twice daily).
Sponsors
The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 40 - 65 years old; 2. Gender: No restrictions; 3. Patients with carotid intima-media thickness (cIMT) of 1.0 mm <= cIMT < 2.0 mm as determined by carotid artery ultrasound examination; 4. High-risk cardiovascular population; such as abnormal blood lipids, hypertension, smoking, obesity, family history of premature cardiovascular disease, etc.; 5. Have basic reading ability, have a smart phone, and be able to use social software such as WeChat; 6. Agree to participate and be able to cooperate with the research and complete the follow-up, provide the signed informed consent form of the research subject.
Exclusion criteria
Exclusion criteria: 1. Subjects with a history or current diagnosis of any tumor; 2. Subjects currently pregnant, those who have been pregnant or lactating in the past two years, or those planning to become pregnant within the next year; 3. Subjects diagnosed with AIDS; 4. Subjects with unstable angina pectoris, those who have experienced acute myocardial infarction within the past six months, or those who have recently undergone surgical intervention; 5. Subjects who are unable to undergo and complete the intervention treatment due to mental disorders, physical disabilities, other medical conditions or physical problems; 6. Subjects who are currently, recently or plan to participate in other clinical trials, weight loss programs or other intervention studies; 7. Subjects currently using weight loss drugs; 8. Subjects using any vitamins or medications that affect homocysteine levels, or subjects currently following the clinical prescribed diet; 9. Subjects with severe cardiovascular diseases, diabetes, liver failure, or life-threatening diseases with a prognosis of less than five years; 10. Subjects that researchers consider to be obstacles to participation or may affect compliance, any other situation that the researchers deem relevant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brachial artery endothelial dilation function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight;Height;Waist circumference;Hip circumference;Body fat percentage;Blood pressure;Oxidative stress level;SAM level;SAH level;tHCY level;Routine blood indexes;Inflammatory factors;Vitamin B12;Lactic Acid; | — |
Countries
China
Contacts
Public ContactXiao Yunjun
The Seventh Affiliated Hospital, Sun Yat-sen University(Shenzhen)
Outcome results
None listed